Research

THERAPY

Essent Biologics Launches Human Mesenchymal Stem Cells For Regenerative Medicine, Biopharmaceutical And Cell Therapy Research | New Products Services

CENTENNIAL, Colo., June 8, 2021 /PRNewswire/ — Essent Biologics, a nonprofit biotechnology company setting a new standard in human-derived biomaterials and comprehensive data for research, today announced the launch of its human mesenchymal stem cells (hMSCs) for regenerative medicine, biopharmaceutical and cell therapy research. Essent Biologics will provide highly-characterized, low-passaged hMSCs. Each vial will contain over one million cells at thaw and have a passage level of P0 or P1 to ensure potency.

The company’s hMSCs are the first commercial hMSC product that is recovered, expanded and cryopreserved without the use of antibiotics or animal products. Additionally, with each order of hMSCs, Essent Biologics can provide full donor information coupled with a source biopsy called the Essent Origin Sample™.

“This is an import milestone in getting our products into the hands of brilliant researchers,” said Corey Stone, Executive Director, Essent Biologics. “Our stem cells are

Read More Read More
TREATMENT

Newport Healthcare’s Mental Health Treatment Efficacy Yields Industry-Leading Outcomes in 2020 | Surveys Polls And Research

NASHVILLE, Tenn., May 20, 2021 /PRNewswire/ — In a year defined by a global pandemic that included social isolation, collective trauma, and unprecedented stress, mental health emerged as a primary concern for families, with as many as three quarters of young people reporting increased mental health issues. Newport Healthcare, a national network of evidence-based healing centers for teens and young adults with primary mental health disorders, responded to the urgent demand for care and, in outcomes data compiled in collaboration with Drexel University’s Center for Family Intervention Science, is reporting statistically significant, industry-leading improvements of patient symptoms following treatment.

Over the course of 2020, 1,400 clients at multiple Newport Healthcare locations – including Newport Academy for teens and Newport Institute for young adults – were surveyed via validated assessment tools including the DSM-5-informed Patient Health Questionnaire (PHQ-9) that measures depression severity, the Generalized Anxiety Disorder Scale (GAD-7), and the

Read More Read More
SUPPLEMENT

Weight Loss Supplement Market Research Report by

New York, June 08, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Weight Loss Supplement Market Research Report by Distribution Channel, by Region – Global Forecast to 2026 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p06088961/?utm_source=GNW

The Global Weight Loss Supplement Market size was estimated at USD 81.57 Billion in 2020 and expected to reach USD 87.70 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 7.84% from 2020 to 2026 to reach USD 128.36 Billion by 2026.

Market Statistics:
The report provides market sizing and forecast across five major currencies – USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation

Read More Read More
TREATMENT

Oral Gepants Have Disrupted Acute Migraine Management and Look Next to Transform Preventive Treatment, According to Both Primary Care Physicians and Specialists | Surveys Polls And Research

EXTON, Pa., May 6, 2021 /PRNewswire/ — Both AbbVie’s (formerly Allergan, an AbbVie company) Ubrelvy and Biohaven’s Nurtec ODT are viewed by primary care physicians (PCPs) as strong entrants into the acute segment of the migraine market following their early 2020 launches. Interestingly, a new study from Spherix found similar physician-reported shares for both gepants [i.e., oral calcitonin gene-related peptide (CGRP) receptor antagonists], despite Ubrelvy’s earlier launch.  

In the inaugural semiannual report included in Spherix’s RealTime Dynamix™: Migraine – PCP Perspective (US) service, data collected from 96 PCPs found that, of the two gepants, direct comparison gives Nurtec ODT the advantage over Ubrelvy on most clinical metrics. Nurtec ODT best differentiates from Ubrelvy on duration of effect and convenience of patient administration among PCPs, consistent with its prevention label currently under FDA review and its unique orally dissolving tablet formulation, respectively.

Spherix has also been tracking the specialist-treated (i.e.,

Read More Read More
TREATMENT

Upcoming Oral, Small Molecule Agents Expected to Leapfrog Existing Biologic Treatment and Become Foundational Inflammatory Bowel Disease Therapies | Surveys Polls And Research

EXTON, Pa., March 24, 2021 /PRNewswire/ — Spherix recently surveyed 100 US gastroenterologists and followed up with seven qualitative interviews (including an industry key opinion leader) in order to assess the current pre-advanced systemic treatment algorithm for inflammatory bowel disease (IBD), along with the prospects for several oral, small molecule pipeline therapies. This new Special Topix™ service was created in response to the three oral, small molecule therapies currently in Phase 3 development for the treatment of IBD and the additional three therapies with Phase 2 clinical data.

Through ongoing research provided in Spherix’s core services offered in IBD, Spherix experts began to notice a possible paradigm shift in the way gastroenterologists are perceiving upcoming pipeline agents and how they intend on prescribing to biologic-naïve patients. The combination of qualitative and quantitative research included in the Special Topix™ service evaluates, in detail, the current treatment algorithm for pre-advanced systemic

Read More Read More
HEALTH

To Tell the Truth: NYT Promotes ‘Study’ From Team Left Advocacy Group as Scientific Health Research

To Tell the Truth is Human Events News’ press analysis series. These stories will focus on “news” being reported by either The New York Times, The Washington Post, ABC News, NBC News, or CBS News. Despite 24-hour cable broadcasts, and an untold number of internet sources, these established, mainstream platforms continue to influence the majority of American citizens and their political opinions.

The “news” generated by these press outlets is better regarded as “opinion” crafted in a way designed to discourage skepticism and critical thought on the part of the audience. To Tell the Truth will be Human Events News’ periodic effort to help address this bias and restore the skepticism necessary on the part of all Americans to maintain a free society.

Last week, the New York Times published via email newsletter a piece titled “How Trump Affected Americans’ Health.

The article, which cited a report from a “respected

Read More Read More